Alembic Pharmaceuticals Schedules Board Meeting to Approve Q2 and H1 FY27 Results
Alembic Pharmaceuticals Ltd 路 Intimation 路 04 Nov 2026, 5:30 am
Alembic Pharmaceuticals Schedules Board Meeting to Approve Q2 and H1 FY27 Results Alembic Pharmaceuticals Limited announced that its Board of Directors will meet on 4th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with the company's insider trading code of conduct, the trading window for dealing in company securities, which closed on 1st Oct'26, will reopen 48 hours after the declaration of the financial results.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
